Silexion Therapeutics Ltd.
SLXNW · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | -0.00 | -0.00 |
| FCF Yield | -39,804.47% | -3,921.89% | -1,186.67% | -501.39% |
| EV / EBITDA | -0.20 | 0.93 | -13.19 | -0.32 |
| Quality | ||||
| ROIC | -2,504.18% | -147.57% | -15.72% | -0.82% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.51 | 0.89 | 0.96 | 1.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -85.38% | -34.55% | -139.83% | -1,776.32% |
| Safety | ||||
| Net Debt / EBITDA | -0.20 | 0.95 | -13.68 | 0.05 |
| Interest Coverage | -241.75 | -520.11 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -13,563.40 | 0.00 | 0.00 | 0.00 |